Results 121 to 130 of about 23,498 (195)

A protocol for RCT for an assessing the relative effectiveness of Tysabri vs. Gilenya in the treatment of RRMS [PDF]

, 2016
Δεληγιάννη, Γεωργία
core   +1 more source

Natalizumab and fumarate treatment differentially modulate CD4+ T cell and B cell subtypes in multiple sclerosis patients without impacting durable COVID-19 vaccine responses. [PDF]

Front Immunol
Curtin R, Velmurugu Y, Dibba F, Hao Y, Nyovanie S, Lopez A, Mieles D, Ng C, Perdomo K, Scott N, Lewin JB, Avila RL, Smrtka J, Patskovsky Y, Howard J, Silverman GJ, Krogsgaard M.   +16 more
europepmc   +1 more source

Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in Italy

ClinicoEconomics and Outcomes Research
Luca Prosperini,1 Lorenzo Pradelli,2 Laura Santoni,3 Daria Perini,3 Salvatore Cottone,4 Marco Vercellino5 1S. Camillo-Forlanini Hospital, Rome, Italy; 2AdRes Health Economics and Outcomes Resources, Turin, Italy; 3Biogen Italia, Milan, Italy; 4Department
Prosperini L, Pradelli L, Santoni L, Perini D, Cottone S, Vercellino M   +5 more
doaj  

Serum drug levels and JCV assay discrepancies after switching from originator to biosimilar natalizumab. [PDF]

BMJ Neurol Open
Høgestøl EA, Brustad ÅW, Celius EG, Meling M, Berg-Hansen P, Kro GB, König M, Schanke Y, Halvorsen B, Warren DJ, Gehin JE, Bolstad N, Nygaard GO.   +12 more
europepmc   +1 more source

Immunogenicity of Hepatitis B Virus Vaccination in Relapsing-Remitting Multiple Sclerosis Patients Under Immunocompromising Treatment. [PDF]

Int J Mol Sci
Cruces-Párraga J, Muñoz-Jurado A, Escribano BM, Martín-Hersog FA, Triguero-Ortiz C, Carmona-Medialdea C, Túnez I, Caballero-Villarraso J, Agüera-Morales E.   +8 more
europepmc   +1 more source

Serum neurofilament light chain as a biomarker of disease control in multiple sclerosis: a real-world cross-sectional analysis of therapeutic regimens. [PDF]

J Neurol
Konitsioti AM, Schweitzer F, Johannis W, Steffen F, Bittner S, Fink GR, Schroeter M, Warnke C.   +7 more
europepmc   +1 more source

Systematic Review of Monoclonal Antibody Therapies in Relapsing Multiple Sclerosis: Comparator-Stratified Analysis of Relapse and Disability Outcomes. [PDF]

Med Sci (Basel)
Ciubotaru A, Grosu C, Maștaleru A, Constantinescu V, Alexa D, Covali R, Riscanu L, Bilcu RV, Cucu LE, Gațcan C, Socolov-Mihaita SA, Lăcătușu D, Crivoi F, Vamanu A, Patrascu A, Ignat EB.   +15 more
europepmc   +1 more source

Integrin β1 Demarks Precursors of Brain-Residing Antibody-Secreting Cells in Multiple Sclerosis. [PDF]

Neurol Neuroimmunol Neuroinflamm
Kuiper KL, Bogers L, Rip J, van Hasselt Y, Melief MJ, Wierenga-Wolf AF, Klein Kranenbarg RAM, Bindels E, van de Werken HJG, de Beukelaar J, Smets I, Wokke B, Smolders J, van Luijn MM.   +13 more
europepmc   +1 more source

Kappa Free Light Chains Reflect Treatment Response and Progression Independent of Focal Inflammation in Multiple Sclerosis. [PDF]

Eur J Neurol
Rosenstein I, Axelsson M, Johnsson M, Malmeström C, Kvartsberg H, Zetterberg H, Lycke J, Novakova L.   +7 more
europepmc   +1 more source

Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy: roles of underlying diseases and immunomodulatory therapies in FAERS. [PDF]

Front Immunol
Lin X, Qin N, He B, Chen J, Zhang Y, Wang H, Liu W.   +6 more
europepmc   +1 more source